Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis Daniel T. GrimaLisa M. BernardDavid C. Mendelssohn Current Opinion 27 December 2012 Pages: 981 - 989
Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years Jane BurchSusan GriffinNerys Woolacott Review Article 27 December 2012 Pages: 991 - 1004
The Burden of Moderate to Severe Psoriasis Giovanna RahoDaniela Mihajlova KolevaLuigi Naldi Review Article 27 December 2012 Pages: 1005 - 1013
Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups Ava John-BaptisteMan Wah YeungMurray Krahn Systematic Review 27 December 2012 Pages: 1015 - 1034
Losing Sight of the Wood for the Trees Paul DolanHenry LeeTessa Peasgood Original Research Article 27 December 2012 Pages: 1035 - 1049
A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand Rajan RagupathyKatri AaltonenDavid Reith Original Research Article 27 December 2012 Pages: 1051 - 1065
The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes Laura PanattoniPaul M. BrownPatrick Gladding Original Research Article 27 December 2012 Pages: 1067 - 1084
The General Public’s Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer’s Disease Medication Mark OremusJean-Eric TarrideNatasha Clayton Original Research Article 27 December 2012 Pages: 1085 - 1095
Erratum to Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model Nguyen C. M.Bounthavong M.Morreale A. P. Erratum 27 December 2012 Pages: 1096 - 1096